From: 6, Alternatives to blood transfusion for patients having surgery: Cell salvage and tranexamic acid
Table 60Base case analysis results (probabilistic analysis), cost-effectiveness, moderate risk
Analysis | Incremental QALYs vs ST | Incremental costs vs ST | INMB at £20K(a) | Probability most CE option | Rank (95% CI) |
---|---|---|---|---|---|
ST | £0 | 0% | 3 (2, 3) | ||
ICS+PCS | 0.000 | £420 | -£423 | 0% | 4 (4, 4) |
PCS | 0.000 | -£108 | £113 | 40% | 2 (1, 3) |
TXA | 0.000 | -£169 | £173 | 60% | 1 (1, 2) |
Abbreviations: CI = confidence intervals; ICS = intra-operative cell salvage; INMB = incremental net monetary benefit; PCS = post-operative cell salvage; QALYs = quality adjusted life years; ST = standard treatment; TXA = tranexamic acid
- a
INMB = NMB intervention A – NMB ST; Highest INMB = most cost-effective option at a £20,000 per QALY threshold; a negative INMB means that ST is more cost-effective than this option.
- Table 60, Base case analysis results (probabilistic analysis), cost-effectivenes...Table 60, Base case analysis results (probabilistic analysis), cost-effectiveness, moderate risk - Blood Transfusion
- PREDICTED: Rattus norvegicus myelin basic protein (Mbp), transcript variant X8, ...PREDICTED: Rattus norvegicus myelin basic protein (Mbp), transcript variant X8, mRNAgi|2678909708|ref|XM_063277092.1|Nucleotide
- 50S ribosomal protein L22 (plastid) [Trillium tschonoskii]50S ribosomal protein L22 (plastid) [Trillium tschonoskii]gi|918020933|ref|YP_009163341.1|Protein
- NADH-plastoquinone oxidoreductase subunit 4 (plastid) [Trillium tschonoskii]NADH-plastoquinone oxidoreductase subunit 4 (plastid) [Trillium tschonoskii]gi|918020918|ref|YP_009163326.1|Protein
- NADH-plastoquinone oxidoreductase subunit 2 (plastid) [Trillium tschonoskii]NADH-plastoquinone oxidoreductase subunit 2 (plastid) [Trillium tschonoskii]gi|918020928|ref|YP_009163336.1|Protein
Your browsing activity is empty.
Activity recording is turned off.
See more...